Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate
Author:
Affiliation:
1. Oncology Medicine Department, Jules Bordet Institute, Université Libre de Bruxelles
Funder
not funded
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14737140.2019.1613892
Reference47 articles.
1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
3. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
4. Adjuvant Therapy for High-Risk Gastrointestinal Stromal Tumour
5. Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics;Clinical Breast Cancer;2023-06
2. KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer;Nature Communications;2023-05-05
3. Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review;BMC Cancer;2021-08-28
4. Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy;Analytical Chemistry;2021-07-29
5. Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents;Anti-Cancer Agents in Medicinal Chemistry;2021-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3